Dianthus Therapeutics (Nasdaq: DNTH) granted equity inducement awards on July 1, 2026 to five newly hired, non-executive employees under Nasdaq Listing Rule 5635(c)(4).
The awards are non-qualified stock options for an aggregate 58,000 shares at an exercise price of $90.21 per share, with a 10-year term and four-year vesting schedule.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – DNTH
-1.06%
-1.06%News Effect
On the day this news was published, DNTH declined 1.06%, reflecting a mild negative market reaction.
Dianthus issued 58,000 non-qualified stock options as inducement grants under Nasdaq Listing Rule 56...
Analysis
Dianthus issued 58,000 non-qualified stock options as inducement grants under Nasdaq Listing Rule 5635(c)(4), continuing a pattern of option-based hiring. With an effective $600,000,000 shelf and elevated short interest, investors may monitor cumulative dilution and insider activity.
Key Figures
Inducement option grants:58,000 sharesOption term:10 yearsExercise price:$90.21 per share+3 more
"made as material inducements to acceptance of employment with Dianthus in accordance with Nasdaq Listing Rule 5635(c)(4)."
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
non-qualified stock optionsfinancial
"The inducement grants consist of non-qualified stock options to purchase an aggregate of 58,000 shares"
Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.
equity inducement planfinancial
"subject to the terms and conditions of the Dianthus Therapeutics, Inc. Equity Inducement Plan"
An equity inducement plan is a program that gives new hires or targeted employees stock, restricted shares, or stock options as a hiring or retention reward, often separate from the company’s regular long-term incentive plans. Think of it as a signing bonus paid in company stock: it helps attract and keep talent but matters to investors because it can dilute existing shares, change executive incentives, and affect future earnings through compensation expense.
stock option agreementfinancial
"and the terms and conditions of a stock option agreement."
A stock option agreement is a formal contract that gives an individual the right to buy or sell a specific number of shares of a company's stock at a set price within a certain period. For investors, it’s an important tool because it can provide opportunities to profit from stock price movements or to protect against potential losses, making it a key element in financial planning and investment strategies.
NEW YORK and WALTHAM, Mass., July 02, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it granted equity awards on July 1, 2026, to five newly-hired, non-executive employees.The inducement grants were approved by the Company's independent Compensation Committee and were made as material inducements to acceptance of employment with Dianthus in accordance with Nasdaq Listing Rule 5635(c)(4).
The inducement grants consist of non-qualified stock options to purchase an aggregate of 58,000 shares of the Company's common stock with a 10-year term and an exercise price of $90.21 per share.The options vest as to 25% on the first anniversary of the vesting commencement date and in equal monthly installments for the following 36 months. The inducement grants are subject to the terms and conditions of the Dianthus Therapeutics, Inc. Equity Inducement Plan, and the terms and conditions of a stock option agreement.
About Dianthus Therapeutics Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who aim to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.
What inducement grants did Dianthus Therapeutics (DNTH) announce on July 2, 2026?
Dianthus Therapeutics announced equity inducement grants of non-qualified stock options covering 58,000 shares. According to Dianthus, these options were granted on July 1, 2026 to five newly hired, non-executive employees as a material inducement to join the company.
What is the exercise price and term of the new Dianthus Therapeutics (DNTH) stock options?
The inducement stock options have an exercise price of $90.21 per share and a 10-year term. According to Dianthus, these options are granted under its Equity Inducement Plan and are governed by individual stock option agreements for each participating employee.
How do the Dianthus Therapeutics (DNTH) inducement stock options vest for new employees?
The options vest 25% on the first anniversary of the vesting commencement date, then monthly over 36 months. According to Dianthus, this structure creates a four-year vesting period, aligning employee incentives with longer-term company performance and retention goals.
Under which Nasdaq rule were the Dianthus Therapeutics (DNTH) inducement grants made?
The inducement grants were made in accordance with Nasdaq Listing Rule 5635(c)(4). According to Dianthus, the independent Compensation Committee approved these non-qualified stock option awards as material inducements for five newly hired, non-executive employees to accept employment with the company.
Who received the July 2026 Dianthus Therapeutics (DNTH) inducement stock option awards?
Five newly hired, non-executive employees received the July 2026 inducement option grants. According to Dianthus, these awards were specifically structured as material inducements to employment and are subject to the Equity Inducement Plan and related stock option agreements.
